Trump's Executive Order: A New Era for Cannabis?
Recently, President Trump's Executive Order made headlines by directing the Department of Justice to consider moving cannabis from Schedule 1 to Schedule 3 of the Controlled Substances Act. This potential change could open the doors for more comprehensive research and broaden the cannabis market significantly.
In CC2C News Special Report, we explore the implications of the recent executive order on cannabis rescheduling, shedding light on key insights from Morgan Fox.
Exploring the Reactions from NORML
Following the executive order, Morgan Fox, the Political Director for NORML, shared his insights with CC2C News. He believes that this shift could finally lead Congress to step in and make the necessary changes to cannabis laws. While the federal government has historically been cautious about cannabis, there seems to be a growing momentum towards reform.
Banking and Hemp: What’s Next?
Fox highlighted how essential banking solutions are for the cannabis industry. If cannabis is downgraded, access to banking services would help numerous businesses thrive. Furthermore, there’s hope for addressing limitations surrounding the hemp industry, aiming to prevent a ban on hemp products that could stifle innovation.
Research Opportunities with Medicinal Cannabis
Perhaps one of the biggest winners in this potential shift is the research community. Moving cannabis to Schedule 3 could lead to more clinical studies, allowing scientists to explore the full medicinal benefits of cannabis. The medicinal-grade cannabis could provide more rigorous evidence for its uses, which may help with acceptance across the board.
As discussions continue and developments unfold, many are watching closely to see how this executive order could reshape the landscape of cannabis in America. Will Congress finally get involved? Only time will tell!
Add Row
Add
Write A Comment